The financing behind a planned divestment often speaks louder than the deal announcement itself. When reports emerged midweek that banks are assembling roughly €1 billion in debt financing for Apax Partners to acquire two Gerresheimer business units, it marked the moment a July-announced sale shifted from intention to execution.
Gerresheimer agreed in late July to offload its Centor unit and Primary Packaging Plastics, its US operation, to the private equity firm. The two divisions generated combined revenue of around €570 million in 2025 and employ approximately 2,400 people. The enterprise value attached to the transaction stands at roughly €1.5 billion, with the Centor closing expected by the end of the current fiscal year and the Primary Packaging Plastics disposal slated to follow in the first half of fiscal 2027.
For shareholders, the debt commitment signals that Apax is serious — and that Gerresheimer’s strategy of shrinking to refocus is gaining momentum. The company intends to concentrate on its core pharmaceutical and healthcare packaging business, using the proceeds to shore up margins and expand its financial headroom for a previously announced transformation offensive.
A Quiet Shareholder Meeting Amid Structural Change
The annual general meeting held on Tuesday passed with little friction. Shareholder turnout reached 41.59 percent of share capital, and all proposed resolutions were approved. Rainer Beaujean, Markus Sieger, and Eva van Pelt joined the supervisory board, with Sieger taking the chairmanship. Board members Uwe Röhrhoff, Wolf Lehmann, and Achim Schalk received discharge for fiscal 2025, and KPMG AG from Düsseldorf was confirmed as auditor for fiscal 2026.
The uneventful meeting contrasts with the turbulence that has marked Gerresheimer’s recent history. Röhrhoff had stepped down from his interim CEO role at his own request, leaving CFO Lehmann and board member Schalk to handle his duties on a temporary basis. The company has weathered multiple leadership changes in recent years, yet the market has largely shrugged off the latest transition.
A Valuation Debate With Unusually Wide Parameters
Investor sentiment around the stock remains deeply divided, and the gap between analyst targets is striking. JPMorgan reaffirmed an “Overweight” rating on Thursday with a price target of €46 — nearly double the current share price. Berenberg, by contrast, maintained “Hold” with a far more sober target of €24 the same day. Deutsche Bank also sits at “Hold” with a €26 objective, while MWB Research raised its target from €12.50 to €20 in late August but kept a “Sell” stance.
The share itself has been trading near its 50-day average of €27.52, closing Thursday at €27.78. That relative stability masks a volatile twelve months: the stock hit €44.88 in September of last year, plunged to €14.90 in February, and remains roughly 38 percent below its yearly high even after climbing about 86 percent off the bottom. Over the past year, the equity has lost roughly a third of its value.
Should investors sell immediately? Or is it worth buying Gerresheimer?
Restructuring periods like this one put extra pressure on leadership teams to keep every operational area running smoothly — including workplace safety compliance. A free toolkit with 41 ready-to-use templates and checklists helps you document risk assessments properly and stay on top of your legal duties. Download the free Risk Assessment Toolkit
Friday brought some relief, with the shares trading at €28.30, up 1.9 percent on the day. The weekly gain stood at 6.8 percent, with a similar 6.6 percent advance over the trailing 30 days. Still, the stock sits 37 percent below its 52-week peak.
The Numbers Behind the Restructuring
Gerresheimer’s most recent annual results, covering fiscal 2025, show a business holding steady amid the overhaul. Revenue reached €2.3 billion, with adjusted EBITDA of €384 million translating to a 16.8 percent margin. Organic revenue growth was modest at 0.3 percent, a figure the company attributed partly to an expected stronger second half of fiscal 2026 and the ongoing implementation of its transformation program.
The company has also mandated Lazard as financial advisor for refinancing the remaining corporate structure after the divestments. A comprehensive debt refinancing forms part of the broader plan to realign the balance sheet once the two divisions are sold.
What the Calendar Holds
Investors now face a series of dates that will test whether the stabilization strategy is working. The half-year financial report for fiscal 2026 is due in September, followed by third-quarter figures in October.
Gerresheimer’s situation reflects a broader pattern among pharmaceutical supply-chain companies that were once considered defensive investments. Demand for drug packaging and delivery systems remains fundamentally steady, but when internal challenges overshadow operational strength, investor confidence can erode quickly. The €1 billion financing package from Apax marks a concrete milestone in Gerresheimer’s reshaping — yet it leaves open the central question of whether the company that emerges from this process will be leaner and stronger, or merely smaller.
Ad
Gerresheimer Stock: Buy or Sell?! New Gerresheimer Analysis from September 4 delivers the answer:
The latest Gerresheimer figures speak for themselves: Urgent action needed for Gerresheimer investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from September 4.
Gerresheimer: Buy or sell? Read more here...
